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BACKGROUND: In Human Immunodeficiency Virus (HIV) infected patients on antiretroviral treatment 
(ART), hepatotoxicity is life threatening. Its outcome may lead to liver failure and death. This study was 
conducted to determine the rate and determinants of elevated alanine amino transferase (ALT) (referred 
as >40IU/L for both males and females). 
METHODS: A cross sectional study was conducted on HIV infected individuals who are on ART and 
suspected of drug resistance at Felege Hiwot Referral Hospital, Bahir Dar from July to December 2012. 
Venous bloods were collected from each patient and processed parallely to determine ALT, number of 
HIV RNAs, CD4 and CD8 T cells count, anti hepatitis C virus (HCV) and hepatitis B surface antigen.  
RESULTS: Out of 269 HIV infected patients receiving ART, 32% were confirmed of grades 1-4 levels of 
elevated ALT. The rate of severe hepatotoxicity (grade 3 and 4) was 1.84%. Patients with increased CD8 
T cell counts (P=0.011; AOR=1.82; CI: 1.12 - 2.54), alcohol over use (P=0.014; AOR = 1.23; CI: 1.36- 
3.29) and detectable HIV-1 RNA copies (P=0.015; AOR=2.07; CI: 1.15-3.74) independently predicts the 
elevation of ALT. 
CONCLUSIONS: In HIV infected patients on ART, extreme elevations of ALT were infrequent but 
minor elevations were common so that patient-linked variables such as use of alcohol intake must be 
taken in to account for better clinical management of ART patients. The role of active HCV co-infection 
on the treatment outcome of ART should be further studied. 
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Highly active antiretroviral therapy (HAART) in 
Human Immuno Deficiency Virus (HIV) 
infected patients has led to dramatic 
improvements in the survival of patients in 
resource-limited settings (1). However, 
antiretroviral drugs have been associated with 
both short and long-term toxicities including 
hepatotoxicity, which may be life threatening 
(1). Elevations in serum hepatic enzymes have 
been described in association with all major 
classes of antiretroviral therapy (ART) (2). 
However, the complexity of medication used in 
antiretroviral therapy complicates the 
understanding of the independent effects of each 
drug in the development of drug induced liver 
injury (2, 3). Therefore, prevention and 
management of antiretroviral therapy related 
toxicity has emerged as a major issue for HIV/ 
AIDS treatment and care (4). The pathogenesis 
of drug-induced liver disease normally involves   
 
1Department of Medical Microbiology, Immunology and Parasitology, Bahirdar University, Ethiopia 
2Bahir Dar Regional Health Bureau Laboratory Center, Bahirdar, Ethiopia 
Corresponding Author: Wondemagegn Mulu, Email: wondem-32@yahoo.com





the participation of the parent drug or its 
metabolite that either affects the cell biochemistry 
directly or indirectly by eliciting an immune 
response (6).  As HIV-infected patients live 
longer, they develop long term manifestations of 
chronic HIV infection and treatment complication 
(6). The severity of ART may range from the 
absence of symptoms to liver decomposition and 
the outcome ranges from spontaneous resolution 
to liver failure and death (7). 
Alanine aminotransferase and Aspartate 
aminotransferase are hepatic enzymes that could 
be used as markers of hepatocellular injury (8).  
Studies have revealed that 14-20 % of adults on 
ART had elevated serum liver enzymes as a 
marker of hepatocellular injury (9). Liver enzyme 
elevations (LEEs) are frequently associated with 
use of potent antiretroviral combination therapy. 
The most well-established risk factors for LEEs 
are chronic hepatitis B and C infections (3, 10). In 
addition, several other parameters (e.g., a greater 
increase in CD4 cell count after the start of 
antiretroviral therapy and higher baseline levels of 
alanine aminotransferase (ALT), systemic 
opportunistic infections, cirrhosis, alcohol or drug 
induced hepatotoxicity, age and gender (11, 12 ) 
are risk factors for LEEs. 
In 2003, Ethiopia defined and included first 
and second line drug regimens in the national 
treatment guidelines, including different HIV-drug 
combinations based on World Health Organization 
(WHO) recommendations and in July 2004, the 
number of people who had been taking ART  was 
10, 400 (13).  There is paucity of information on 
the extent and risk factors for ART related 
hepatotoxicity associated with the concentration of 
HIV-1 viral load, HIV co-infections with hepatitis 
C and  B viruses in Ethiopia especially at Felege 
Hiwot Referral Hospital. Thus, the purpose of this 
study was to determine serum alanine 
aminotransferase levels as markers of 
hepatotoxicity in HIV-infected patients receiving 
ART associated with risk factors such as 
concentration of HIV RNA copies (viral load), 
hepatitis C and B virus co-infections and CD4 and 
CD8 T cells. 
 
METHODS AND PARTICIPANTS 
 
A hospital based cross sectional study among HIV 
infected patients on ART and suspected of drug 
resistance was conducted from July to December 
2012 at Felege Hiwot Referral Hospital, Bahir 
Dar, Northwest Ethiopia. The hospital has 273 
beds offering different specialized services 
including ART services in its ART clinic (14). 
Felege-Hiwot Referral Hospital is one of the 
government-sponsored ART centers at Bahir Dar 
Town. The ART clinic provides follow-up service 
for pre-ART patients and patients who are on ART 
to both pediatrics and adults by specialists and 
trained health professionals. It provides the ART 
service for those HIV patients who are found in 
Bahir Dar and its vicinity. In addition, the hospital 
accepts ART referred patients from different parts 
of the region (15). 
A structured questionnaire was used for 
collection of data on socio-demographic 
characteristics and other associated risk factors 
such as WHO categories of the patient, history of 
current tuberculosis treatment and use of alcohol. 
A total of 269 HIV infected patients receiving 
antiretroviral therapy during the study period were 
included conveniently. Number of HIV RNA 
copies, level of alanine aminotransferase, CD4 and 
CD8 lymphocyte count, anti HCV and HBsAg 
detection were done during the time of viral load 
detection for antiretroviral regimen change.  
Ten ml of venous blood was collected using 
K3 EDTA on vacutainer tube from each 
participant. From this 10ml, 50µl of blood was 
taken for CD4 and CD8 T cells count. The 
remaining amount of venous blood was used for 
the preparation of serum and plasma for the 
analysis of serum ALT and HIV RNA copies; 4 
ml of EDTA anticoagulated blood was taken and 
allowed to stand a certain period of time and then 
centrifuged to obtain the plasma.  
         Simultaneously, another 4ml of blood was 
taken and allowed to coagulate after which it was 
centrifuged at 3000 rpm for 5 minutes to obtain 
sera.  The level of alanine amino transferase 
(ALT) was measured on a Beckman Coulter 
Synchron Clinical Systems auto lab Analyzer 
(Beckman Coulter Inc. Fullerton, CA, USA). 
Specifically, ALT was measured using a 
pyruvate/lactate dehydrogenase method.  The test 
was carried out using the mono reagent procedure. 
The working reagent was prepared by mixing 4 
volumes of reagent one (R1) in 1 volume of 
reagent two (R2). The auto lab analyzer was 
calibrated for ALT. A series of labeled test tubes, 




i.e. Blank, normal control and patients from 1, 
2….n
th   
were used
   
according to the number of 
samples to be analyzed. The preparation was 
mixed and the first reading of absorbance was 
executed after 90 seconds at 37°C. The change in 
absorbance per minute was then calculated. 
Normal value for ALT (SGPT) at 37°C: 0- 40 
IU/L was taken for both Women and Men. 
For the determination of HIV RNA copies, 
200 µl of plasma was prepared from K3 EDTA 
collected tube and samples extracted automatically 
using Abbott Real Time HIV-1 assay (Abbott 
Molecular Inc., Des Plaines, IL, USA) as per 
manufacturer’s instructions. The extracted 
samples were amplified and detected on the m 
2000 rt platforms according to the manufacturers 
instruction. The result of the finding was 
interpreted as: detectable (RNA copies > 150 
copies/ ml of blood), detectable but under lower 
detection limit (RNA copies of < 150) and non– 
detectable (Target value was not detected within 
the given sample). 
Absolute CD4  and CD8 T cells count was 
performed using a specific monoclonal antibody 
and fluorescence-activated cell sorting (FACS 
count) (BECTON DJCKINSON,  USA) which is a 
single platform. According to the manufacturer’s 
instruction, 50µl of whole blood from k3 EDTA 
collected tube was added using an automated 
electronic pipette to each tube provided. The tubes 
were vortexed upside down then upright for 5 
seconds and incubated for 60-120 minutes in the 
dark at room temperature. Then 50 µl of fixative 
solution provided in the reagent kit was added into 
each tube after the tubes were vortexed, stained 
samples were analyzed by the FACS count double 
tube software. 
Serological assay for the presence of hepatitis 
B surface antigens (HBsAg) was performed on 
sera using EILSA, (Linear chemicals, Joaquim 
Costa, Barcelona, Spain) according to the 
manufacturer’s manual instructions. Similarly, 
IgG and IgM antibodies to HCV were detected 
using ELISA, (Linear chemicals, Joaquim Costa, 
Barcelona, Spain). 
Data were entered and analyzed using SPSS 
version 16 software. Independent sample T test 
was used for group mean comparison of CD4 T 
cell counts.  Pearson χ
2 
test and bivariate were 
used for categorical data to generate P-values and 
P-value <0.05 was considered statistically 
significant. Multivariate logistic regression 
analysis was done to identify the independent 
determinant factors of ALT elevations. The study 
was approved by the Research and Ethical 
Committee of Bahir Dar University and written 
informed consent was obtained from each study 
participant.
 
The following WHO operational definitions 
were used: 
Toxicity of degree 0: the level of toxicity which is 
considered as normal in which its value is >1.25 x 
normal value of ALT in serum 
Toxicity of degree 1:  the Level of toxicity  which 
is considered as  weak  in which its value is  1.256 
– 2.5 x normal value of ALT in serum 
Toxicity of degree 2:   the Level of toxicity which 
is considered as moderate in which its value is 2.6 
– 5 x normal value of ALT in serum 
Toxicity of degree 3:   the Level of toxicity which 
is considered as severe in which its value is 5.1 – 
10 x normal value of ALT in serum 
Toxicity of degree 4: the Level of toxicity which 
is considered as   severe in which its value is >10 
x normal value of ALT in serum 
No alcohol intake: For those patients who never 
had a habit of drinking alcohol  
Moderate alcohol intake: drinking weekly and 
less than 5 drinks per occasion 
Heavy alcohol intake: drinking weekly and > 5 




A total of 269 HIV infected patients receiving 
ART were included in this study.  Of these, 137 
(51%) were males and 132 (49%) females with a 
median age of 35, ranging from 11 to 75 years. 
Among the 269 study participants, 233 (86.6%) 
were urban dwellers while 36 (13.4%) were from 
rural areas (Table 1). According to the World 
Health Organization (WHO) category of HIV 
stages, the majority (71.4%) of HIV-infected 
patients were in stage III whereas 9.7% were in 
stage IV (Table 4). The overall prevalence of 
hepatotoxicity (alanine aminotransferase 
elevation) in HIV-infected patients receiving ART 
was 32%. The hepatotoxicity rate was similar 
between males (32%) and females (31.8%) 
(P=0.958). Statistically significant association was 
not observed among the different age groups 
(P=0.748). The rate of alanine aminotransferase 





elevation was higher in HIV ART patients living 
in rural areas (44%) than urban residents (30%) 
(Table1). 
Table 1: Alanine amino transferase elevations in relation to sex, age and residence groups of HIV 




                                  
            Alanine amino transferase status 
 
P - value 
 
 
    Elevated 
     No. (%) 
Not elevated 
 No. (%) 
Total 






        44 (32) 
42 (31.8) 
        86 (32) 
 
93 (68) 
  90 (68.2) 
183 (68) 
 
137 (51)                          0.958 
132 (49) 
269 (100) 


































10 (3.7)                  
84 (31.2)           
105 (39              
51 (19)                            0.748  
19 (7.1)             
269 (100) 
 




From 269 HIV infected patients on ART, 86 
(32%) developed grade 1- 4 levels of toxicity, of 
which 60 (22.3 %) was grade 1 levels, 21 (7.8%) 
grade 2 levels and 3 (1.1%) and 2 (0.74%) were 




































Grades of toxicity 
 
Figure 1: Frequency of grades of alanine amino transferase elevations in HIV infected patients on ART at 
FHRH, Bahir Dar, July - December, 2012. 
 
Of the 269 ART patients who participated with 
known HBV/HCV serology, 30 (11.2%) were 
HBsAg positive, 51 (18.96 %) were anti-HCV 
positive and 8 (3%) were both HBsAg and anti-
HCV positive (Table 2). Ten out of 30 (45%) and 
18 out of 51 (33%) of the patients who were 
HBsAg positive or anti-HCV positive, 




respectively, showed elevated levels of alanine 
amino transferase. Out of eight patients who tested  
 positive for both HBsAg and anti-HCV 4 (50%) 
develop alanine amino transferase elevation. 
However, the difference was not statistical 




Figure 2:  Rate of liver toxicity among hepatitis C, hepatitis B virus and both hepatitis B and C co infected 
ART patients at FHRH, Bahir Dar, July - December, 2012. 
 
The rate of liver enzyme elevation among patients 
who had their viral load was detected, undetected 
and under lower detection limit was 42 (39.3%), 
38 (29.2%) and 6 (19.4%) respectively. In the case 
of liver toxicity, statistically significant 
association was observed between patients having 
detected viral load and non-detected viral load 
(P=0.046) using chi-square test. Significant 
association between hepatitis virus co-infection 
(HCV, HBV) and rate of ALT elevation were not 
observed (Table 2). 
The rate of ALT elevations did not show 
statistically significant association (P=0.463) 
among patients who have a CD4 T cell value 





 (25.8%) and > 1301 cells/mm
3
 (50%) 
respectively. However, the rate of ALT elevation 
among patients who have a CD8 T cell value 







 were 13 (28.3%), 46 
(27.3%) and 26 (49.1%) respectively and the 
difference was statistically significant (P= 0.011). 
The proportion of ALT elevation among heavy 
alcohol user was 7(41.2%). This was much higher 
than those who did not receive any alcohols 
45/174 (25.9%)  (P=0.011)  (Table 2). 
Increasing the mean CD4 T cell count was 
not a determinant factor for the elevation of 
alanine aminotransferase. Statistically significant 
association was found between increased mean of 
CD8 T cell count and liver toxicity (Table 3). Of 
the 269 study participants, 78 (29%) were treated 
for pulmonary tuberculosis. Tuberculosis treated 
patients had higher glutamic pyruvate 
transaminase (GPT) mean value (40.3) than the 














Table 2: The risk factor analysis to rate of alanine aminotransferase elevations among the total study 
participants at FHRH, Bahir Dar, July - December, 2012. 
       
 
Potential risk factors 
             Alanine amino transferase        
P-value  
  Elevated 
  No. (%) 
Not elevated 
 No. (%) 
Total 
No. (%) 
HIV RNA level 
 Detected 
 Undetected 





6  (19.4) 
 
65 (60.7)                            
92 (70.8)                 







    
Number of CD4 T cell  
0- 499 cells/mm3 
 500-1300 cells/mm3 






159 (67.7)                                                                                  








Number of CD8  T cells 
 0-319 cells/mm3 
 320-1800 cells/mm3 






33 (71.7)                                         
122 (72.6) 






    
0.011 
CD4/ CD8 ratio  
 0.0-0.49 cells/mm3 




                                     







 No intake 
 Moderate intake 





   
129 (74.1)            
44 (56.4) 





































































Table 3: Hepatotoxicity among HIV infected patients on ART with the CD4 and CD8 T cell count at 
FHRH, Bahir Dar,*- July - December, 2012. 
 
Liver toxicity Mean of CD4  




Mean of CD8  
T cell count/mm3 
 
 
P - value 
CD4:CD8 
   ratio 
 
 







0.01    0.26 
   0.29 
0.406 
 




Table 4:  Mean of SGPT with the current Tuberculosis therapy and WHO stages among HIV infected 










TB treatment status 
Currently TB treated 





























WHO, World Health Organizations; TB, Tuberculosis, SGPT, Serum glutamate pyruvate transaminase 
 
Socio demographic variables, hepatitis C and B 
virus co-infections and those variables that 
showed significance in the bivariate analysis at 
levels of less than or equal to 0.2 were included in 
the multivariate analysis. From this variables, only 
the presence of detectable amount of HIV RNA 
copies (P = 0.015; AOR=2.07; CI: 1.15-3.74), 
over use of alcohol (P = 0.014; AOR=1.23; CI: 
1.36-3.29) and an increased CD8 T lymphocytes 
(P = 0.012, AOR=1.82; CI: 1.12-2.54) 
independently predicts the elevated level of 
alanine amino transferase (Table 5).
 
Table 5:  Multivariate analysis of risk factors for grade 1- 4 hepatotoxicity in HIV-1 infected patients while 
receiving concomitant antiretroviral therapy at FHRH, Bahir Dar, July - December, 2012. 
TB, Tuberculosis; AOR, adjusted odds ratio; CI, Confidence interval, HCV; Hepatitis C virus, HBsAg;  




Liver toxicity, including grade 1- 4, is a serious 
health problem and contributes substantially to a 
large morbidity, mortality, prolonged hospital stay 
and therapy (16). In the present study, an attempt 
was made to determine the rate of ALT elevations, 
detect the presence of hepatitis B and C virus co-
infections in HIV infectd ART patients and to 
identify potential risk factors for the elevation of 
ALT anticipating better management of patients 
and control of liver toxicity. 
The overall rate of liver toxicity in HIV-ART 
patients was 32%. The reason for this high rate of 
toxicity might be attributed to concurrent hepatitis 
B and C virus infections, overuse of alcohol and 
   
Variables 
                  
                                  AOR (95 % CI)                                              P - value 
    
Age                              1.025  (0.997, 1.055)    0.077 
Sex                              1.199 (0.680, 2.111)    0.530 
Residence                             0.114  (0.013, 1.026)    0.048 
Alcoholism                              1.215 (1.357, 3.293)    0.014 
Anti-HCV                              0.913 (0.452, 1.844)    0.799 
HBsAg                             1.175 (0.501, 2.756)    0.712 
Mean of CD8 T cell                        
TB treatment 
     
                        
                         
    1.823 (1.121,   2.541) 
       
    0.867  (0.4691, 1.602)                
   0.016 
    
   0.493 
HIV RNA level       2.072  (1.147, 3.742)    0.015  





other medical conditions. This finding is 
comparable with findings of similar studies 
conducted elsewhere by Mankhatithan et al (2), 
Crumciaflone et al (17) where the rate of  grade  
1- 4 toxicity were 31.4% and 27%  respectively.  
However, our finding differs from studies carried 
out in other countries such as South Africa (18), 
Cameron (19) and France (20) where elevation 
rate of 23 %, 22.6 % and 20.9 % were reported 
respectively. The difference could be due to the 
higher prevalence of hepatitis B and C co- 
infections in our patients compared to those of the 
other studies.  
In the present study, severe hepatotoxicity 
(grade 3 or 4 as defined by the WHO) was 
observed in 1.84 % of the study participants. This 
finding is consistent with other studies carried out 
in Uganda (1) and Thailand (4) that showed 2.9 % 
and 1.3 % of severe hepatotoxicity respectively. 
However, very high rate of severe hepatotoxicity 
was reported in other studies conducted on HIV 
infected ART patients by Sulkowski et al (3) and 
Mankhatithan et al (2) that indicated 10.4% and 
17.7%, respectively. The wide variations in the 
rate of severe hepatotoxicity reported in our study 
and previous studies is probably because of 
differences in the population characteristics, 
different definitions of severe hepatotoxicity and 
the frequency of patient follow-up, monitoring and 
duration of therapy. 
Sex difference has not been found to be a 
determinant factor for elevated ALT (P=0.958). 
This is probably because the courses of HIV 
pathogenesis and drug metabolism in humans 
generally are not sex dependent. This finding is 
similar with the findings of previous studies 
carried out in different countries such as Nigeria 
(6), Cameron (20), South Africa (21), Swiss (22) 
and Brazil (23).  As found out in this study, age 
difference is not also a determinant factor for liver 
enzyme elevations. This could be due to the fact 
that more than 90 % of the cases were individuals 
up to 50 years of age. There are also studies which 
support that age is not a risk factor for 
development of hepatotoxicity in patients taking 
ART drugs (22, 24, 25). However, there are also 
studies which support that age > 50 years is a risk 
factor for hepatotoxicity in patients taking ART 
drugs. 
  In this study, a higher ALT elevation was 
revealed in HIV-ART patients co-infected with 
HCV (35.3%) compared to the mono-HIV 
infected group (31.2%). However, unlike other 
authors such as Mankhatithan et al (2),  Livry et al 
(18)  and Yimer et al (24),  we did not find 
statistically significant differences (P=0.799, 
AOR= 0.913, CI = 0.452-1.844). The possible 
reason for the observed difference might be that 
some of the HCV infections may not be at active 
(replicated) stage because we did not identify 
active HCV co-infections because we detect the 
antibody rather than the antigen. In this study, no 
difference of rate of hepatotoxicity observed 
between HBV co-infected (33.3%) and   mono 
HIV infected group (31.8%). However, our 
finding contradicts with findings of Mankhatithan 
et al in South East Asian (2), Livry  et al in France 
(18) and Gisolf et al in Belgium (25) that reported 
co-infection with HBV was a risk factor. 
  In unadjusted analyses, detectable HIV RNA 
copies  or a high HIV RNA load was associated 
with the rate of liver toxicity in these study 
(P=0.015, AOR=2.072, CI = 1.147-3.742) as 
indicated by  other  studies  carried out in Swiss 
by  kovari et al (22) and by Forrester et al (26).  
This might be because higher levels of HIV RNA 
copies would lead to greater rates of apoptosis and 
necroinflammatory activity. Such apoptosis and 
necroinflammatory activity could be expected to 
elevate liver enzymes in a manner dependent on 
HIV viral load as it was explained by Forrester et 
al (26). 
A statistically significant association was 
found between increased CD8 lymphocyte count 
and rate of ALT elevations. This might be due to 
the presence of an immunologic mechanism for 
the development of hepatotoxicity. The other 
possible explanations might be that patients with 
low CD4 and increased CD8  lymphocyte counts 
are more prone in acquiring opportunistic 
infections-this might necessitate consumption of 
different drugs leading to subclinical liver damage 
and there by increased susceptibility for liver 
enzyme elevations while taking anti HIV as 
indicated by  Yimer et al  in Ethiopia (24). 
Overuse of alcohol (P=0.014) has been found 
to be a risk factor in this study.The same is true in 
studies carried out by kovari et al (22). The high 
rate of elevated ALT among alcohol over user 
patients might be due to  the direct hepatocellular 
damaging effect of the alcohol that will leads to 
release of ALT from liver cells. Importantly, on 




bivariate analysis, we found out a statistically 
significant association between previous 
tuberculosis treatment (P=0.01) and rate of alt 
elevations. However, on multivariate analysis, we 
did not find associations between hepatotoxicity 
and tuberculosis therapy (P=0.493).  
In conclusion, the rate of elevated ALT 
identified in this study, was high.  The occurrence 
of an elevated alanine amino transferase is 
independently influenced by overuse of alcohol, 
history of tuberculosis therapy and the presence of 
detectable number of HIV RNA. Therefore, 
patient-linked variables must be taken into account 
for better clinical management of HIV infected 
ART patients. HCV co-infections need to be taken 
into account in the management of HIV-infected 
patients, in particular when the initiation of 
antiretroviral therapy is considered. Further study 
on the role of active HCV co infection on the 
treatment outcome of ART and rate of 
hepatotoxicity from onset of ART and the role of 
the individual antiretroviral drugs to elevation of 
ALT should be done. 
The study has some limitations, however. 
The relation of liver toxicity with the onset or 
duration of ART has not been done. We also 
carried out detection of anti HCV rather than 
detecting its antigen as a result we did not identify 
whether the infection was active or chronic, and 
the involvement of the type of regimen to the 
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